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Lifestyle factors such as lower BMI, higher levels of physical activity, and
increased fruit and vegetable intake, have been shown to benefit breast cancer survival,
but the association between these factors and the pathologic complete response (pCR) to
chemotherapy, has not been studied. We investigated whether lifestyle factors including
BMI, physical activity, diet and alcohol use are associated with pCR from neoadjuvant
chemotherapy for breast cancer treatment. Secondarily, we assessed whether the relative
dose intensity (RDI) of neoadjuvant chemotherapy is associated with pCR.
We conducted a retrospective study of women treated with neoadjuvant
chemotherapy for stage I-III breast cancer between 2010 and 2016 at Yale New Haven
Hospital-Smilow Cancer Hospital. Through medical record review, we determined BMI,
tumor characteristics, pCR vs residual disease, and chemotherapy dates and doses. The
RDI of treatment was calculated for each patient using published methods. A telephone
survey administered to a subset of women assessed physical activity, fruit and vegetable
intake, and alcohol intake during the year prior to diagnosis. Unconditional logistic
regression models identified factors associated with pCR.
In our cohort (n=243), the average age was 53 years (SD 13) and mean BMI was
29.5 kg/m2 (SD 7.0). Seventy-five (31%) patients had pCR and 168 (69%) had residual
disease. Patients with pCR had lower mean BMI than those with residual disease (28.2

(SD) vs. 30.1 (SD), p=0.04). Fifty-eight patients (24%) received <85% RDI. pCR was not
associated with optimal (>85%) RDI.
The results of our study suggest that lower BMI is associated with pCR. Although
we did not find an association between RDI and pCR, a high proportion of patients in our
study received suboptimal RDI <85%, highlighting the need for interventions targeting
the tolerability of and adherence to chemotherapy. Future research should be done to
assess if adoption of healthy behaviors to achieve weight loss during treatment produces
similar results in terms of pathologic outcomes from treatment.

ACKNOWLEDGEMENTS
I would like to thank my mentor and advisor for this work, Dr. Tara Sanft for providing
invaluable guidance since the beginning of this project. Thank you for supporting me in
my medical journey as well, and for being a role model for developing a career as a
physician and investigator. I would also like to thank Fangyong Li for his statistical
expertise and for performing a large portion of the data analysis for this work, as well as
Drs. Melinda Irwin and Brenda Cartmel for their insights throughout this project. Lastly,
I would like to thank my family and Aaron Hakim for their unwavering support
throughout medical school.

TABLE OF CONTENTS
INTRODUCTION .......................................................................................................... 1
Neoadjuvant Chemotherapy for Breast Cancer ............................................................ 1
Neoadjuvant Chemotherapy Regimens ........................................................................ 2
Pathologic Complete Response.................................................................................... 5
Relative Dose Intensity................................................................................................ 6
Obesity and Breast Cancer........................................................................................... 7
Physical Activity and Breast Cancer ............................................................................ 9
Metabolic Syndrome ................................................................................................. 11
Cancer Prevention Guidelines ................................................................................... 12
STATEMENT OF PURPOSE ....................................................................................... 13
METHODS ................................................................................................................... 14
Patient Selection and Recruitment ............................................................................. 15
Medical Record Review ............................................................................................ 16
Adherence to Lifestyle Recommendations Measurement ........................................... 17
Relative Dose Intensity Measurement ........................................................................ 18
Reasons for Reduced RDI ......................................................................................... 19
Data Analysis ............................................................................................................ 19
RESULTS ..................................................................................................................... 21
Factors associated with pCR ...................................................................................... 24
Association between pCR and RDI............................................................................ 27
Factors associated with RDI ...................................................................................... 27
Reasons for Reduced RDI ......................................................................................... 31
DISCUSSION ............................................................................................................... 33
Pathologic Complete Response.................................................................................. 33
Relative Dose Intensity.............................................................................................. 36
Limitations ................................................................................................................ 40
Conclusions ............................................................................................................... 41
REFERENCES ............................................................................................................. 42

1

INTRODUCTION1
Breast cancer is diagnosed in more than 250,000 women each year in the United
States, making it the second most common cancer in women, behind nonmelanoma skin
cancer (2). The majority of cases are diagnosed at an early stage, with 92% of cases
diagnosed in the curable setting (stages I-III) (3). The current approach to treatment of
early-stage disease is evolving, but modalities typically include surgery, radiation,
chemotherapy and/or endocrine therapy (4). The treatment outcomes are generally good,
with a 5-year survival rate of 98% for those diagnosed with localized disease, and 85%
for those with disease spread to reginal lymph nodes (3). Chemotherapy is an essential
treatment component for higher-risk patients to prevent recurrence (4). To date, very few
people have studied the association between having a pathologic response to
chemotherapy and lifestyle factors such as physical activity, BMI, and diseases
associated with metabolic syndrome.
Neoadjuvant Chemotherapy for Breast Cancer
Neoadjuvant chemotherapy is a treatment option for patients with locallyadvanced breast cancer in which chemotherapy is given prior to surgery. This approach is
in contrast to adjuvant chemotherapy, in which treatment is given post-operatively.
Neoadjuvant chemotherapy was first introduced in the 1970s as a treatment for locallyadvanced inoperable disease in order to make surgical resection possible (5). However,
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its use has now expanded to early stage, operable disease in order to reduce tumor
volume and allow for more women to be able to choose breast-conserving surgery (6).
The rate of preoperative neoadjuvant therapy for breast cancer in the United
States has increased dramatically, from 12.2% in 2003 to 24.0% by 2011 (7). The
National Comprehensive Cancer Network guidelines recommend neoadjuvant therapy in
patients with locally advanced disease, and suggest considering it in patients with stage
IIA, IIB, or IIIA and limited lymph node disease, especially if breast conservation is
desired (7).
Several studies have shown that there is no difference in long-term survival for
patients receiving neoadjuvant chemotherapy compared with adjuvant chemotherapy (8,
9). However, a recent meta-analysis of 12 clinical trials provides strong evidence that in
patients with human epidermal growth factor receptor 2 (HER-2) positive disease,
neoadjuvant chemotherapy did have a survival benefit (10). Additionally, a randomized
controlled trial of adjuvant vs neoadjuvant chemotherapy for early stage breast cancer
with tumors larger than 2cm found that neoadjuvant chemotherapy resulted in less
extensive resection with no increase in re-excision rates (11).
Neoadjuvant Chemotherapy Regimens
Most regimens used in neoadjuvant chemotherapy for breast cancer contain an
anthracycline (A), cyclophosphamide (C) and/or a taxane (T) (Table 1) (12). The most
common regimens use these drugs sequentially, such as 4 cycles of AC every 3 weeks
followed by 12 cycles of weekly T (AC-T). Recent studies have shown that dose-dense
AC (ddAC) regimens that include 2-week rather than 3-week cycles of AC have
improved survival (13). Deviations from this standard anthracycline plus taxane regimen,
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such as an anthracycline-free regimen (TC) have been used in patients who cannot or do
not wish to be treated with anthracyclines. Other regimens sometimes used according to
physician or patient preference include 5-fluorouracil, epirubicin and cyclophosphamide
(FEC), FEC plus docetaxel (FEC-D), or cyclophosphamide, methotrexate, and 5fluorouracil (CMF) (12). In patients with triple-negative breast cancer, the addition of a
platinum agent may lead to a better response to neoadjuvant chemotherapy (14).
In HER-2 positive disease, the addition of trastuzumab to neoadjuvant
chemotherapy is standard of care, and has been shown to at least double the
chemotherapy response rate in these patients compared with chemotherapy alone (15).
The recent “APHINITY” randomized controlled trial found that the addition of
pertuzumab to trastuzumab and chemotherapy for adjuvant therapy of HER-2 positive
tumors led to significantly improved survival (16). Studies have also shown benefit from
the combination of pertuzumab and trastuzumab along with chemotherapy in the
neoadjuvant setting (12).

Table 1. Common Neoadjuvant Chemotherapy Regimens for Breast Cancer
Abbreviation

Regimen

Doses

HER2-negative breast cancer regimensA
AC – T

ddAC – TB

4 x doxorubicin +
cyclophosphamide every 3
weeks, then 12 x paclitaxel
weekly
4 x doxorubicin +
cyclophosphamide every 2
weeks, then 12 x paclitaxel
weekly

Doxorubicin: 60mg/m2
Cyclophosphamide: 600mg/m2
Paclitaxel: 80mg/m2
Doxorubicin: 60mg/m2
Cyclophosphamide: 600mg/m2
Paclitaxel: 80mg/m2

4
AC - ddT

TC
TAC
CMF
FEC

4 x doxorubicin +
cyclophosphamide every 3
weeks, then 4 x paclitaxel every
2 weeks
4 x docetaxel +
cyclophosphamide every 3
weeks
6 x docetaxel + doxorubicin +
cyclophosphamide every 3
weeks
6 x cyclophosphamide +
methotrexate + fluorouracil
every 3 or 4 weeks
6 x fluorouracil + epirubicin +
cyclophosphamide every 3
weeks

Doxorubicin: 60mg/m2
Cyclophosphamide: 600mg/m2
Paclitaxel: 175mg/m2
Docetaxel: 75mg/m2
Cyclophosphamide: 600mg/m2
Docetaxel: 75mg/m2
Cyclophosphamide: 600mg/m2
Doxorubicin: 60mg/m2
Cyclophosphamide: 600mg/m2
Methotrexate: 40mg/m2
Fluorouracil: 600mg/m2
Fluorouracil: 500mg/m2
Epirubicin: 100mg/m2
Cyclophosphamide: 500mg/m2

HER2-positive breast cancer regimens (alone or in combination with above)

A

TH

12 x paclitaxel + trastuzumab
weekly

TCH

6 x docetaxel + carboplatin +
trastuzumab every 3 weeks

THCP

6 x docetaxel + carboplatin +
trastuzumab + pertuzumab
every 3 weeks

THP

6 x docetaxel + trastuzumab +
pertuzumab every 3 weeks

Trastuzumab: 2mg/kg (4mg/kg
loading dose on week 1)
Paclitaxel: 80mg/m2
Docetaxel: 75mg/m2
Carboplatin: AUCC = 6mg/mL/min
Trastuzumab: 6mg/kg (8mg/kg
loading dose on week 1)
Docetaxel: 75mg/m2
Carboplatin: AUC = 6mg/mL/min
Trastuzumab: 6mg/kg (8mg/kg
loading dose on week 1)
Pertuzumab: 420mg (840mg loading
dose on week 1)
Docetaxel: 75mg/m2
Trastuzumab: 6mg/kg (8mg/kg
loading dose on week 1)
Pertuzumab: 420mg (840mg loading
dose on week 1)

HER2: human epidermal growth factor receptor 2
dd: dose-dense
C
AUC: Area under the concentration x time curve. The AUC is calculated according to
the patient’s renal function using the Calvert formula, which is Total dose (mg) = Target
AUC x (GFR + 25).
B

5
Pathologic Complete Response
One of the advantages of neoadjuvant chemotherapy is the ability to assess an
individual tumor’s response to a particular chemotherapy regimen. Response to treatment
can be assessed both during treatment by clinical examination or imaging and after
surgical resection by pathologic examination of the tissue. Information about the chemosensitivity of the tumor to specific agents can be useful in helping to guide subsequent
drug selection, as response-guided treatment can only be done when the tumor is
available for monitoring (17). Additionally, pathological examination of resected tissue
following neoadjuvant chemotherapy allows for the determination of a pathological
complete response (pCR), which is defined as having no residual invasive cancer in the
breast and axillary nodes.
A pCR at the time of breast surgery has been shown to be a favorable prognostic
factor associated with longer survival than those with residual disease (10, 18, 19). For
example, a pooled analysis by Cortazar and colleagues found a significant association
between pCR and disease-free and overall survival (18). In another analysis, the same
research group also found that the correlation of pCR with overall survival is greatest in
breast cancer patients with the most aggressive tumor subtypes, such as triple-negative
and HER-2 positive/hormone receptor negative tumors (10). Spring and colleagues
analyzed the relationship between pCR and long-term survival in women under age 40,
and they found a significant increase in survival in those patients who attained pCR
compared to those with residual disease (19).
Studies investigating pCR as an outcome measure of neoadjuvant chemotherapy
have found that the rates of pCR are associated with a variety of factors including patient
age, tumor stage, hormone receptor status, and cellular markers (18, 20, 21). For
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example, it has been repeatedly shown that the rate of pCR is higher for estrogen receptor
(ER) negative compared with ER-positive tumors, which is hypothesized to be due to a
higher rate of tumor cell turnover in ER-negative tumors (5, 10). In their analysis of
women under age 40, Spring and colleagues found that patients with HER2 positive and
triple negative tumors had significantly higher rates of pCR than those with HER2
negative/hormone receptor positive tumors (19). Unsurprisingly, smaller initial tumor
size and lower clinical stage at diagnosis have also been shown to be associated with
higher rates of pCR (19, 21).
Relative Dose Intensity
The relative dose intensity (RDI) of chemotherapy has emerged as an important
indicator that reflects the tolerability and the degree of adherence to the prescribed
chemotherapy regimen. The dose intensity (DI) is a measure of the drug delivered per
unit time (eg. mg/m2/week), and the RDI is defined as the ratio of the actual received
dose intensity to the prescribed dose intensity (22). There are two factors that contribute
to reduced RDI: dose delays or dose reductions. A growing body of evidence supports the
notion that maintaining the RDI of chemotherapy regimens has a mortality benefit for
breast cancer patients (23-26). A recent meta-analysis by the Early Breast Cancer
Trialists’ Collaborative Group found that increased dose intensity of adjuvant
chemotherapy reduces the 10-year risk of breast cancer recurrence and death (25). A
threshold of >85% RDI has been suggested as a cutoff below which the response to
chemotherapy may be suboptimal (23).
Due to the increased understanding and utilization of supportive measures during
chemotherapy, especially granulocyte colony-stimulating factor (G-CSF), it is now

7
possible to maintain the DI of chemotherapy with less chance of reaching dose-limiting
toxicities (25). However, there is clear evidence that despite these advances, many breast
cancer patients still receive suboptimal RDI of their chemotherapy. Denduluri and
colleagues studied the incidence of reduced RDI in a large cohort of breast cancer
patients receiving either adjuvant or neoadjuvant chemotherapy in community oncology
practices. Their study found that over a quarter of breast cancer patients had RDI <85%
across the adjuvant and neoadjuvant groups, but that the RDI varied considerably by
patient age, body surface area, and chemotherapy regimen (27). Similarly, Weycker and
colleagues also found that just over a quarter of early stage breast cancer patients treated
in community oncology practices experienced RDI <85% (28).
Despite the evidence ascribing a mortality benefit to maintaining adequate RDI,
there is a paucity of literature showing a connection between RDI and pCR rates in
neoadjuvant chemotherapy. One small Chinese study of 141 breast cancer patients by
Sun and colleagues found that patients who received more than 6 cycles of neoadjuvant
chemotherapy had higher rates of pCR than those who received less than 6 cycles (29).
Obesity and Breast Cancer
It has been shown that obesity is associated with an increased risk of breast cancer
as well as with poorer overall outcomes including higher risk of recurrence, diseasespecific mortality, and overall mortality (30-33). A large meta-analysis by Chan and
colleagues in 2014 found that women with obesity at the time of breast cancer diagnosis
had a 41% higher risk for total mortality and 35% increased risk for breast cancer
mortality compared with normal weight women (33). Niraula and colleagues found that
the association between obesity and poorer breast cancer prognosis did not change

8
according to tumor subtype (i.e. HER-2, hormone receptor) or menopausal status (34).
However, a more recent study of Korean breast cancer patients found that obesity was a
negative prognostic indicator for hormone-receptor (HR) positive patients but not for HR
negative patients (35).
The relationship between obesity and pCR rates from neoadjuvant chemotherapy
for breast cancer is not as well understood, with data from recent studies reporting mixed
results (36-39). For example, a large single-center study of 1,169 patients by Litton and
colleagues found that higher BMI was associated with lower rates of pCR as well as
worse overall survival (36). A more recent study by Karatas and colleagues had similar
findings that obesity was an independent predictor of lower pCR rates (39). In contrast,
Kogwa and colleagues did not find an association between higher BMI and lower pCR
rates in a sample of 1,000 patients with locally advanced breast cancer (37). However, the
results of this study did show that changes in BMI during treatment may be more strongly
associated with pCR rates than a single BMI measurement, as normal or underweight
patients who gained weight during treatment were more likely to attain pCR than those
whose weight stayed the same (37).
A few studies have investigated the relationship between obesity and RDI during
neoadjuvant chemotherapy. Raman and colleagues found that patients with obesity had
more dose reductions during neoadjuvant chemotherapy than normal weight patients, and
these dose reductions significantly decreased the odds of attaining a pCR in patients with
obesity (40). A study by Yuan and colleagues found that in patients receiving either
adjuvant or neoadjuvant chemotherapy for breast cancer, neither BMI nor body surface
area (BSA) was associated with reduced RDI (41). They did find, however, that worse
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physical function and increased biomarkers of aging (IL-6 and D-dimer) were
significantly associated with reduced RDI.
Physical Activity and Breast Cancer
Engaging in regular physical activity has been shown to lower the risk of breast
cancer, as well as to improve outcomes after diagnosis (42-45). Higher levels of physical
activity following breast cancer diagnosis has been associated with reduced breast cancer
mortality (46-50). Holmes and colleagues found that women who engaged in moderate
physical activity for 3 to 5 hours per week after diagnosis had a significantly reduced risk
of death from breast cancer compared with women who exercised less than 1 hour per
week (46). Lahart and colleagues found that physical activity was also associated with a
reduced risk of breast cancer events, including progression, new primaries, and
recurrence (50).
Changes in physical activity from pre- to post-diagnosis may also influence breast
cancer survival, as several studies have shown that increases in physical activity from
before to after diagnosis had a survival benefit (48, 51). In an analysis of physical activity
among breast cancer patients, Irwin and Colleagues found that women who maintained or
increased their physical activity levels to recommended levels after diagnosis had lower
mortality risk, even if they were inactive before diagnosis (48). Borch and colleagues
found a higher mortality risk among women who reduced their physical activity levels
following a breast cancer diagnosis (52).
The relationship between pre-diagnosis physical activity and breast cancer
outcomes has been investigated, but with more inconsistent findings (48, 51-56). A
number of studies found associations between higher pre-diagnosis physical activity and
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greater survival after breast cancer (48, 51, 53, 54). A large cohort study of women
diagnosed with breast cancer in California found that women with higher levels of longterm physical activity (high school through age 54 years) prior to diagnosis had a lower
risk of breast cancer death (53). However, several studies did not observe such an
association (52, 56). A study of recreational physical activity levels over 10 years prior to
breast cancer diagnosis in over 4,000 women found that higher levels of recreational
physical activity levels was associated with lower all-cause mortality, but did not affect
breast cancer-specific mortality (56).
These studies on physical activity and breast cancer survival did not specifically
look at outcomes for women treated with neoadjuvant chemotherapy. While the link
between physical activity and response rates to neoadjuvant chemotherapy is not well
understood, a few feasibility studies have implemented physical activity programs during
neoadjuvant chemotherapy in order to improve outcomes (57, 58). An aerobic training
intervention during neoadjuvant chemotherapy led to improvements in measures of
cardiopulmonary function as well as patient-reported quality of life and fatigue (57).
It has been suggested in prior studies that a potential reason for the benefit of
physical activity on breast cancer mortality may be that more active patients are better
able to tolerate chemotherapy, and therefore are more likely to complete the full course of
prescribed chemotherapy (48). Several studies have examined the relationship between
physical activity and the RDI of chemotherapy for breast cancer, although these studies
have focused on adjuvant, rather than neoadjuvant, chemotherapy (59, 60). Van Waart
and colleagues conducted a randomized controlled trial comparing a physical activity
intervention during adjuvant chemotherapy for breast cancer to usual care. They found
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that patients in the exercise program required fewer dose reductions than patients in the
usual care group (59). An exploratory analysis of this trial data by Courneya and
colleagues found that the patients in the exercise group had higher RDI than the control
group (61). In a later subgroup analysis by the same group, the strongest effect for
exercising on disease free survival was found to be on patients who received >85% RDI,
suggesting that exercise may be most effective in those patients who received optimal
chemotherapy dosing (60). A recent randomized trial conducted by Carayol and
colleagues found that patients randomized to a diet and exercise intervention during
adjuvant breast cancer therapy were more likely to receive more than 95% of their
planned RDI compared to those receiving usual care, although this finding did not reach
statistical significance (62).
Metabolic Syndrome
The metabolic syndrome (MetS) is defined by the National Cholesterol Education
Program as a collection of metabolic factors including lipid profile, triglycerides,
hypertension, and elevated blood glucose (63). Although there are several different
society guidelines for MetS, it is commonly diagnosed when patients meet three of the
five components: 1) elevated waist circumference, 2) high triglyceride level, 3) low highdensity lipoprotein cholesterol (HDL), 4) elevated blood pressure, or 5) elevated fasting
blood glucose (63) . Patients undergoing drug treatment for high triglycerides, elevated
blood pressure, or elevated fasting blood glucose are also considered to meet criteria.
In addition to the known cardiovascular risks, several studies have also shown
that MetS is associated with poorer breast cancer outcomes such as increased breast
cancer risk, all-cause mortality, and disease recurrence (64, 65). A recent prospective
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study conducted by Dieli-Conwright and colleagues showed that MetS components
worsen during both adjuvant and neoadjuvant chemotherapy (66). In a study of Irish
postmenopausal breast cancer patients, Healey and colleagues found that metabolic
syndrome was more prevalent in the breast cancer patients than in the general population
(65). Their analysis of tumor pathology within their patient sample suggests that MetS
may cause growth factor and receptor changes that lead to more aggressive tumor biology
in breast cancer patients. A study by Duggan and colleagues found that higher insulin
resistance was significantly associated with breast cancer mortality (67). They also found
that higher levels of adiponectin, a peptide hormone inversely correlated with BMI, was
associated with a decreased risk of breast cancer related death.
Cancer Prevention Guidelines
The World Cancer Research Fund (WCRF) and the American Institute for Cancer
Research (AICR) have developed lifestyle recommendations to aid in the prevention of
the most common cancers, including breast cancer. The WCRF/AICR guidelines were
released in 2007, and contain eight recommendations including maintaining a healthy
weight, physical activity, a healthy diet with a variety of fruits and vegetables and limited
red and processed meat, and limiting alcohol intake (68). Following these guidelines has
been associated with lower rates of MetS as well as with lower risk of breast cancer and
improved quality of life in breast cancer survivors (68-71). It is not known how
adherence to these guidelines prior to breast cancer diagnosis affects the pathologic
response to chemotherapy.
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STATEMENT OF PURPOSE
We seek to investigate the demographic, clinical, and lifestyle factors that are associated
with a pathological complete response to neoadjuvant chemotherapy for breast cancer.
We also assess whether pathological complete response is associated with maintaining an
optimal relative dose intensity of treatment. Secondarily, we investigate if the factors
examined in the pathologic complete response analysis are associated with suboptimal
relative dose intensity. Finally, we describe the most common reasons for suboptimal
dose intensity in this cohort of neoadjuvant chemotherapy patients.
Specific Aims:
Aim 1
To investigate the association between lifestyle factors including BMI, diet, physical
activity, and metabolic syndrome markers, and pathologic complete response from
neoadjuvant chemotherapy for breast cancer.
Aim 2a.
To determine if maintaining an optimal relative dose intensity of treatment is associated
with a pathologic complete response to neoadjuvant chemotherapy.
Aim 2b.
To explore if the lifestyle and demographic factors investigated in the pathologic
complete response analysis are associated with optimal relative dose intensity.
Aim 2c.
To describe the most common reasons for reduced relative dose intensity among
patients treated with neoadjuvant chemotherapy for breast cancer.
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METHODS
We conducted a retrospective study to examine the association between pCR and
demographic, clinical, and lifestyle factors, including BMI, diet, alcohol, and physical
activity, for women treated with neoadjuvant chemotherapy for early stage (I-III) breast
cancer between the years 2010 and 2016 (Figure 1). We also assessed the association
between these factors and RDI and evaluated the association between optimal RDI
(>85%) and pCR. This study was approved by the Human Investigation Committee at
Yale University (HIC protocol 2000021102).
The conception and design of this work was done by Ilana Usiskin, Tara Sanft,
Brenda Cartmel, and Melinda Irwin. Obtaining HIC approval was done by Ilana Usiskin
and Tara Sanft. The data collection was performed by Ilana Usiskin. Quality assurance
was done by periodic case reviews and checks of random samples, reviewed with Tara
Sanft. Ilana Usiskin performed basic data analysis, and Fangyong Li provided statistical
expertise and performed the regressions and multivariate data analysis. Interpretation of
the data was performed by Ilana Usiskin, Fangyong Li, and Tara Sanft. This thesis was
written by Ilana Usiskin, and Tara Sanft contributed critical revisions to its content.
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Figure 1. Study design showing the origin of the data. Adherence to cancer prevention
guidelines (physical activity, alcohol, fruit and vegetable intake) in the year prior to
diagnosis was assessed retrospectively via telephone survey. The tumor registry and
electronic medical record (EMR) provided information including BMI pre-and posttreatment, medications for diseases associated with metabolic syndrome, and
chemotherapy treatments.
Patient Selection and Recruitment
We identified eligible participants using the Yale Cancer Center Tumor Registry,
a database of all patients treated for cancer at Smilow Cancer Hospital at Yale New
Haven Hospital (YNHH) and the Yale Cancer Center. Eligible patients were females over
age 18 treated with neoadjuvant chemotherapy for early stage (I-III) invasive breast
cancer during the years 2010 to 2016. Included patients received neoadjuvant
chemotherapy followed by surgical resection and had a pathology report following
surgery available that recorded either pCR or residual disease. Eligible patients needed to
have sufficient treatment information recorded in the electronic medical record (EMR) to
determine chemotherapy treatment information, including the medications given, doses,
and treatment dates. Patients treated with a clinical trial chemotherapy regimen were
excluded from the study.
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For the telephone survey, participants needed to be able to understand and
respond to questions in English, and we excluded patients who had disease recurrence or
who had died. We sent emails to the medical oncologists of patients deemed eligible for
the telephone survey with a 14 day opt-out period to give the oncologists an opportunity
to request that certain patients not be contacted. Of the patients with physician approval,
we attempted to contact patients over the phone using no more than 3 call attempts.
Medical Record Review
We conducted a medical record review using data from the Yale Cancer Center
Tumor Registry and the electronic medical record (EMR) at YNHH. Information
obtained from the tumor registry included demographic information, age at diagnosis,
AJCC tumor staging (72), tumor markers, hormone receptor status, medical oncologist,
as well as pathologic response to neoadjuvant chemotherapy (pCR vs. residual disease).
The determination of pCR or residual disease recorded in the tumor registry for each
patient was verified using the official pathology report in the EMR. Hormone-receptor
status was determined using the tumor registry, and patients with either progesteronereceptor positivity or estrogen-receptor positivity were considered to be hormonereceptor positive. HER-2 status was determined based on whether patients were
prescribed trastuzumab, with or without pertuzumab. This determination was made
because the tumor registry only contained immunohistochemical (IHC) testing results for
HER2, and many patients with indeterminate IHC results for HER2 had positive
Fluorescence In Situ Hybridization (FISH) testing for HER2, which qualifies for
treatment with trastuzumab.
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Data abstracted from the EMR included measured BMI before treatment,
menopausal status, and whether the patient was taking any medications for diabetes,
hypertension, and hyperlipidemia at the time of diagnosis. Chemotherapy treatment
information was recorded for each patient. We recorded the medications, doses, and dates
of administration for all chemotherapeutic medications given prior to surgery.
Adherence to Lifestyle Recommendations Measurement
We determined adherence to the WCRF/AICR cancer prevention lifestyle
recommendations in three domains: physical activity, fruit and vegetable intake, and
alcohol consumption (68). These factors were assessed using a telephone survey asking
patients to recall their activity and diet during the year prior to diagnosis. Verbal
informed consent was obtained over the telephone before proceeding with the survey.
Participants were asked if they ate more than 5 fruit and vegetable servings per day and
how many alcoholic beverages they consumed each week on average. To assess physical
activity, we used the Modifiable Activity Questionnaire developed by Kriska and
colleagues (73). This questionnaire was designed to assess physical activity levels in the
past and asks participants to recall an approximate number of hours per week spent doing
recreational activities such as walking, jogging, using the stair-master, and playing tennis
during the year prior to breast cancer diagnosis. A $5 coffee shop gift card was offered to
participants for completing the survey.
The metabolic equivalent of task-hours per week (MET-h) was determined by
multiplying the hours per week spent on each activity by the estimated MET value of that
activity (74). For example, running at a pace of 10 to 12 minutes per mile is an estimated
9 METs per hour, whereas fast walking at a pace of 15 to 20 minutes per mile is an
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estimated 3.5 METs per hour. We considered exercisers to be those who completed at
least 7.5 MET-hours per week, which is the equivalent of the CDC recommendation of
150 minutes per week of moderate-intensity exercise at 3 METs or greater (75).
Relative Dose Intensity Measurement
Chemotherapy treatment information was collected through review of each
patient’s medical record. The prescribed treatment regimen was determined using the
primary oncologist’s initial consultation note detailing the planned therapy along with the
oncologic treatment schedule recorded in the medical record. All chemotherapy
treatments given prior to surgery were recorded, and any deviations from the planned
treatment that would cause a reduction in the relative dose intensity (RDI) were noted,
including dose reductions and dose delays. A cycle delay was defined as a delay longer
than 7 days from the date the medication was scheduled to be administered.
The RDI for each patient was calculated according to previously published
methods (22). The RDI for each drug in the treatment regimen was calculated separately,
and a total RDI for each patient was then calculated by taking the average of all of the
medications. A patient’s RDI could be lowered by two treatment changes: a dose
reduction or delay in treatment. The total number of treatment weeks was defined as the
weeks between the first day of the first cycle and the last day of the last cycle for each
medication. If medications were given sequentially (i.e. AC-T), the number of treatment
weeks for the first drug was defined as the weeks between the first day of that drug and
the first day of the next drug. Therefore delays in between sequential medications were
reflected in a longer number of treatment weeks for the first drug. Patients who had
planned on completing a medication and signed consent for the medication but did not
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receive the medication due to a medical reason were assigned a RDI of 0 for that
medication. The equations below describe the calculations used to determine the dose
intensity (DI) and RDI for each medication:

𝐷𝑜𝑠𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (𝐷𝐼) =

𝑇𝑜𝑡𝑎𝑙 𝑚𝑔 𝑑𝑟𝑢𝑔
𝐵𝑆𝐴 𝑥 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑤𝑒𝑒𝑘𝑠

𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐷𝑜𝑠𝑒 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 (𝑅𝐷𝐼) =

𝐴𝑐𝑡𝑢𝑎𝑙 𝐷𝐼 𝑓𝑜𝑟 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑝𝑎𝑡𝑖𝑒𝑛𝑡
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑒𝑑 𝐷𝐼 𝑓𝑜𝑟 𝑡ℎ𝑒 𝑟𝑒𝑔𝑖𝑚𝑒𝑛

Reasons for Reduced RDI
We determined the most common reasons for reductions in RDI in the cohort
through medical record review. For each reduction in RDI (by either dose reduction or
cycle delay), the physicians’ documentation was reviewed to determine the reason for the
RDI reduction. When there were two reasons noted for a single reduction, the more
severe symptom was recorded (i.e. neutropenic fever requiring hospitalization was
recorded instead of a mild rash). We did not record treatment side effects for subjects
who did not have a reduced RDI.
Data Analysis
The data was recorded and compiled using the OnCore Enterprise Research data
management system. We compared the demographic and cancer-related characteristics of
the all patients who underwent medical record review with the participants who
completed the telephone survey to ensure that the telephone survey was a representative
sample of the larger cohort. We conducted univariate analyses to identify factors
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associated with pCR, and then performed multivariate analyses to determine if significant
associations remained after adjusting for potential cofounders.
For the RDI analysis, we calculated the average RDI for each patient as described
above in the section above on relative dose intensity measurement. We performed a twosided t-test to determine if there was a difference in pCR rates between patients with
>85% RDI and those with <85% RDI. We then performed a univariate analysis to
identify if the demographic and lifestyle factors used in the pCR analysis were associated
with RDI >85%. All statistical analyses were performed using SAS 9.4 (Cary, NC).
Significance level was set as p-value < 0.05, two-sided.
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RESULTS
We assessed the eligibility of 393 patients who received neoadjuvant
chemotherapy for breast cancer at Yale New Haven Hospital between the years 2010 and
2016 (Figure 2). Ninety-eight patients did not have treatment information recorded in the
EMR because the data was not transferred from paper records. We conducted 243
medical record reviews of eligible patients. Of the 243 patients reviewed, we attempted to
contact 149 over the phone and completed 67 surveys (Figure 2). Of the 243 patients, 6
did not have sufficient chemotherapy dosage information recorded in the medical record
to accurately calculate RDI. Two of these patients completed the telephone survey,
leaving 65 survey-completers with sufficient information to calculate RDI.

Figure 2. This flow diagram shows the number of subjects at each stage of recruitment
for the study. Ultimately, 243 patients were included in the medical record review and 67
patients completed the telephone survey. The arrows to the right show the numbers of
subjects who were not included going forward, and the reasons for exclusion.
A
Six patients had insufficient chemotherapy doses recorded in the EMR to calculate RDI.
Two of these patients completed the survey. We calculated the RDI for 237 patients in
the medical record review group, and 65 patients in the telephone survey group.
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The overall sample of 243 patients included in the medical record review had an
average age of 52.9 (SD 13.0) years at diagnosis and a mean pre-treatment BMI of 29.5
kg/m2 (SD 7.0). The patients were 74% non-Hispanic White, and 44% were
premenopausal. Most of the patients had AJCC stage II cancer at diagnosis (55%), with
17% stage I and 28% stage III. The most common hormone-receptor (HR) and HER2
status of the patients was HR-positive, HER2-negative (38%) and 28% of patients were
triple-negative. Eighty-three patients (34%) were HER2-positive.
Most patients were prescribed an initial regimen of
anthracycline/cyclophosphamide plus taxane, which consists of four cycles of the
anthracycline/cyclophosphamide delivered every two or three weeks (63% of patients).
Thirteen percent of patients were prescribed a taxane-only regimen, which consisted of
paclitaxel, docetaxel, or albumin-bound paclitaxel, with or without cyclophosphamide.
Other less-common initial regimens included fluorouracil, epirubicin, plus
cyclophosphamide (FEC) and cyclophosphamide, methotrexate, plus fluorouracil (CMF)
(6%). About a third of patients (33%) were prescribed a regimen containing trastuzumab,
with or without pertuzumab.
The 67 patients who completed the telephone survey did not significantly differ
from the overall sample in terms of demographics, BMI, tumor characteristics, or number
of patients with RDI < 85% (Table 2). The only significant difference between the phone
survey completers and the overall sample was within the chemotherapy treatments
prescribed, with fewer participants in the overall sample prescribed a regimen of Taxane
+ Anthracycline + Platinum than those completing the phone survey.
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Table 2. Sample Characteristics

Age at diagnosis, mean(SD)
Race (n, %)
White, non-Hispanic
Black, non-Hispanic
Hispanic
Other (unknown)
Premenopausal (n, %)
AJCC Stage at Diagnosis (no,%)A
I
II
III
Hormone Receptor Status (n,%)B
HR-, HER2HR-, HER2+
HR+, HER2HR+, HER2+
BMI, mean(SD)
Prescribed Chemotherapy Regimen (n, %)C
Anthracycline onlyD
Taxane onlyE
Taxane + Anthracycline
Taxane + Anthracycline + Platinum
Taxane + Platinum
CMF / FECF
Prescribed Trastuzumab (n,%)
A

Overall
(n=243)
52.9 (13.0)

Telephone
Survey (n=67)
54.8 (12.2)

180 (74%)
38 (16%)
18 (7%)
7 (3%)
108 (44%)

54 (80%)
10 (15%)
3 (4%)
0
25 (37%)

42 (17%)
134 (55%)
68 (28%)

14 (21%)
36 (54%)
17 (25%)

pvalue
0.17
0.23

0.4
0.57

0.13
67 (28%)
26 (11%)
93 (38%)
57 (23%)
29.5 (7.0)

14 (21%)
7 (10%)
29 (43%)
17 (25%)
29.7 (7.9)

5 (2%)
31 (13%)
149 (63%)
17 (7%)
20 (8%)
15 (6%)
81 (33%)

1 (2%)
9 (14%)
44 (68%)
0
10 (15%)
4 (6%)
23 (34%)

0.76
0.03

0.84

AJCC: American Joint Committee on Cancer
HR: Hormone receptor (estrogen-receptor or progesterone-receptor). HER2: human epidermal growth
factor receptor 2
C
n=237 because 6 patients had insufficiently detailed chemotherapy information to calculate RDI
D
Anthracycline regimens contained an anthracycline (doxorubicin) plus cyclophosphamide
E
Taxanes included paclitaxel, docetaxel, or albumin-bound paclitaxel
F
CMF = Cyclophosphamide, methotrexate, and fluorouracil; FEC = Fluorouracil, epirubicin, and
cyclophosphamide
B
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Factors associated with pCR
Of the sample of 243 patients, 75 (31%) had a pCR and 168 (69%) had residual
disease following neoadjuvant chemotherapy (Table 3). Patients who had a pCR had a
lower BMI prior to breast cancer diagnosis than those with residual disease (28.2 (SD
5.9) vs. 30.1 (SD 7.4), p=0.04). Patients with HR-negative/HER-2 positive tumors were
most likely to have a pCR (69% of HR-/HER2+ patients). In contrast, patients with HRpositive/HER-2 negative tumors were least likely to have a pCR (12%). The AJCC stage
at the time of diagnosis was also associated with pCR, with patients diagnosed at AJCC
stage I more likely to have pCR (44%) than with patients diagnosed at AJCC stage III
(15%) (p=0.002). Age at diagnosis, race, and menopausal status were not significantly
associated with pCR status. Being prescribed medication for diabetes, hypertension, or
hyperlipidemia was also not associated with pCR.
In the exploratory analysis of the 67 patients who completed the telephone survey,
no lifestyle factors (physical activity (exercise > 7.5 MET-hours per week), eating more
than 5 daily servings of fruit and vegetables, or drinking more than 1 alcoholic beverage
per week) were associated with pCR status.
In the multivariate analysis, after controlling for age at diagnosis, hormone
receptor status and AJCC stage at diagnosis, baseline BMI remained a significant
predictor of pCR (Table 4). The adjusted odds ratio of higher BMI on pCR was 0.95
(95% CI 0.91 – 0.997, p=0.04). Hormone receptor status also remained an independent
predictor of pCR in the adjusted analysis. The adjusted odds ratio of HR-/HER2+
compared with HR-/HER2- was 6.95 (95% CI 2.08, 23.17, p<0.001). The adjusted odds
ratio of HR+/HER2- compared with HR-/HER2- was 0.43 (95% CI 0.21 – 0.89,
p<0.001).

25
Table 3. Univariate associations between patients’ demographics, clinical factors,
lifestyle factors and pCR

Age at diagnosis, mean(SD)
Race/Ethnicity(n, %)
White, non-Hispanic
Black, non-Hispanic
Hispanic
Other (unknown)
Premenopausal (n, %)
AJCC Stage at diagnosis (n,%)A
I
II
III
Hormone Receptor Status (n,%)B
HR-, HER2HR-, HER2+
HR+, HER2HR+, HER2+
BMI, mean(SD)
Medication for DM, HTN, or HLD (n,%)C
Yes
No
Of those completing phone survey
(n=67):
Exercise >7.5 MET-h/week (n,%) D
Yes
No
Fruit and vegetable >5 servings/day (n,%)
Yes
No
Alcohol >1 drink/week, (n,%)
Yes
No
A

Residual
Disease (n=168)

pCR
(n=75)

53.6 (13.0)

51.6 (12.8)

126 (70%)
24 (63%)
13 (72%)
5 (71%)
67 (63%)

54 (30%)
14 (37%)
5 (28%)
2 (29%)
40 (37%)

23 (56%)
86 (65%)
58 (85%)

18 (44%)
47 (35%)
10 (15%)

p-value
0.28
0.85

0.11
0.002

<0.0001
45 (68%)
8 (31%)
83 (88%)
31 (54%)
30.1 (7.4)

21 (32%)
18 (69%)
11 (12%)
26 (46%)
28.2 (5.9)

73 (74%)
95 (66%)

26 (26%)
49 (34%)

R (n=46)

pCR
(n=21)

0.04
0.2

p-value
0.95

31 (69%)
15 (68%)

14 (31%)
7 (32%)
0.27

22 (76%)
24 (63%)

7 (24%)
14 (37%)
0.3

26 (74%)
20 (63%)

9 (26%)
12 (38%)

AJCC: American Joint Committee on Cancer
HR: Hormone receptor (estrogen-receptor or progesterone-receptor). HER2: human epidermal growth
factor receptor 2
C
DM: Diabetes Mellitus; HTN: Hypertension; HLD: Hyperlipidemia
D
MET-h = metabolic equivalent of task-hours per week
B
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Table 4. Multivariate associations of pCR, demographics, clinical factors, and lifestyle
factors
Unadjusted analysis
Adjusted analysis
Predictors
pOR (95% CI)
p-value
OR (95% CI)
value
Baseline BMI
0.96 (0.92, 1.00)
0.06
0.95 (0.91, 1.00)
0.04
Age at diagnosis, years
0.99 (0.97, 1.01)
0.27
0.98 (0.96, 1.00)
0.09
Hormone receptor statusA
<.0001
<.0001
HR-, HER2+
6.13 (1.99, 18.84) 0.0004 6.95 (2.08, 23.17) <0.001
HR+, HER20.41 (0.20, 0.82) <.0001
0.43 (0.21, 0.89) <.0001
HR+,HER2+
1.83 (0.81, 4.13)
0.45
1.70 (0.72, 3.98)
0.69
HR-, HER21
1
AJCC stage at Diagnosis
<0.003
0.06
(n, %)B
I
4.54 (1.82, 11.29)
0.01
3.12 (1.17, 8.28)
0.06
II
3.17 (1.48, 6.77)
0.18
2.20 (0.98, 4.94)
0.48
III
1
1
A
B

HR: Hormone receptor (estrogen-receptor or progesterone-receptor). HER2: human epidermal growth
AJCC: American Joint Committee on Cancer
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Association between pCR and RDI
Two-hundred thirty-seven patients had sufficient chemotherapy dosage
information recorded in the EMR to accurately calculate the RDI of treatment. Of the 237
patients, 179 (76%) had RDI between 85% and 100%, and 58 (24%) had RDI <85%
(Table 5). Ninety-three patients (39%) had an RDI of 100%, meaning they completed
treatment without any delays or dose reductions. Of the patients with a pCR, 78% had an
RDI >85%, which was not significantly greater than the 74% of patients with residual
disease who had RDI >85% (p=0.49).

Factors associated with RDI
In a secondary analysis, we investigated if the same demographic, clinical, and
lifestyle factors from the pCR analysis were associated with completing treatment with an
optimal RDI of >85%. Patients with RDI >85% were younger than those who did not,
with a mean age of 51.7 years (SD 13.1) compared to a mean age of 56.4 years (SD 11.9)
for RDI <85% (p=0.02). Being premenopausal was associated with RDI >85%
(p=0.003). Among those taking medications for these diabetes, hypertension, or
hyperlipidemia, 69% had RDI >85%, whereas 80% those not taking such medications
had RDI >85% (p=0.056). Ethnicity, hormone-receptor status, AJCC stage and initial
chemotherapy regimen did not show an association with completing chemotherapy with
RDI above 85%. BMI was not associated with RDI.
Sixty-five patients who completed the telephone survey had sufficient dosage
information in the EMR to calculate RDI. In the exploratory analysis of this subset of
patients, those who reported exercising more than 7.5 MET-hours per week prior to
diagnosis were more likely to complete chemotherapy at an RDI above 85% than those
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who did not exercise at these levels (81% vs 54%, p=0.024). Patients who reported
drinking more than one alcoholic beverage per week were also more likely to have an
RDI above 85% (p=0.012). Fruit and vegetable intake above 5 daily servings was not
associated with RDI.
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Table 5. Univariate associations between patients’ demographics, clinical factors,
lifestyle factors, and RDI
RDI ≥ 85%
(n=179)A

RDI < 85%
(n=58)

p-value

Pathologic response (n,%)
Residual Disease
pCR

121 (74%)
58 (78%)

42 (26%)
16 (22%)

Age at diagnosis, mean(SD)

51.7 (13.1)

56.4 (11.9)

0.02

88 (84%)

17 (16%)

0.003

Premenopausal (n,%)
Race/Ethnicity (n,%)
White, non-Hispanic
Black, non-Hispanic
Hispanic
Other (unknown)
AJCC stage at diagnosis (n,%)C
I
II
III
HER/HER2 Status (n,%)B
HR-, HER2HR-, HER2+
HR+, HER2HR+, HER2+
BMI, mean(SD)
Medication for DM, HTN or HLD (n,%)D
Yes
No

0.49

0.91
131 (75%)
29 (74%)
14 (82%)
5 (71%)

43 (25%)
10 (26%)
3 (18%)
2 (29%)
0.44

29 (73%)
102 (79%)
48 (72%)

11 (28%)
27 (21%)
19 (28%)
0.63

46 (72%)
19 (73%)
69 (75%)
45 (82%)
29.5 (6.4)

18 (28%)
7 (27%)
23 (25%)
10 (18%)
29.8 (9.7)

66 (69%)
110 (80%)

30 (31%)
28 (20%)

Prescribed chemotherapy regimen (n,%)
Anthracycline onlyE
F

Taxane only

Taxane + Anthracycline
Platinun-containing
CMF/FECG
Prescribed Trastuzumab (n, %)

0.74
0.056

0.53
4 (80%)

1 (20%)

22 (71%)

9 (29%)

118 (79%)

31 (21%)

25 (68%)
10 (67%)

12 (32%)
5 (33%)

64 (79%)

17 (21%)

0.37

30

Of those completing phone survey (n=65):
Exercise >7.5 MET-h/week (n,%) H
Yes
No
Fruit and vegetable >5 servings/day (n,%)
Yes
No
Alcohol >1 drink/week, (n,%)
Yes
No
A

RDI ≥ 85%
(n=49)

RDI < 85%
(n=16)

p-value
0.024

43 (81%)
12 (54%)

10 (19%)
10 (46%)
0.093

24 (86%)
25 (68%)

4 (14%)
12 (32%)
0.012

30 (88%)
19 (61%)

4 (12%)
12 (39%)

Total n=237 because 6 patients had insufficiently detailed chemotherapy information to calculate RDI
HR: Hormone receptor (estrogen-receptor or progesterone-receptor). HER2: human epidermal growth
factor receptor 2
C
AJCC: American Joint Committee on Cancer
D
DM: Diabetes Mellitus; HTN: Hypertension; HLD: Hyperlipidemia
E
Anthracycline regimens contained an anthracycline (doxorubicin) plus cyclophosphamide
F
Taxanes included paclitaxel, docetaxel, or albumin-bound paclitaxel
G
CMF = Cyclophosphamide, methotrexate, and fluorouracil; FEC = Fluorouracil, epirubicin, and
cyclophosphamide
H
MET-h = metabolic equivalent of task-hours per week
B
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Reasons for Reduced RDI
Of the 237 patients included in the RDI analysis, 144 patients (61%) completed
treatment with lower RDI than prescribed (less than 100%), due to either dose reduction
or dose delay on at least one cycle of chemotherapy. Fifty-eight patients had RDI <85%,
below the threshold for optimal treatment effect. For these subjects with RDI <85%, we
describe the treatment factors and adverse effects associated with RDI reduction.
Among those with suboptimal RDI <85%, neuropathy was the most common
reason for dose reduction with 29% of patients in this group receiving a dose reduction
due to neuropathy (Table 6). Fatigue and other medical reasons were the next most
common reasons for dose reductions among those with RDI <85%, each with 19% of
subjects in this group. Neuropathy was still the most common reason for dose reduction
in those maintaining RDI >85%, with 14% of patients in this group experiencing a dose
reduction due to neuropathy. The most common reasons for dose delays in patients
receiving adequate RDI >85% were skin toxicity (11%) and myelosuppression (10%).
Twenty-six percent of the patients with suboptimal RDI experienced a cycle delay of
more than 7 days due to a personal reason, which included vacations, patient preference,
or convenience delays between treatments that were not noted to be due to any medical
reason.
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Table 6. Reasons for RDI reductions in patients <85% RDI (n=58)A
Reason for RDI Reduction

Delay

Dose Reduction

Neuropathy
7%
29%
Myelosuppression
17%
16%
Febrile neutropenia
2%
12%
Nausea and vomiting
0%
2%
Constipation/diarrhea
3%
5%
Infection
12%
9%
Cardiac signs or symptoms
2%
2%
Pain
3%
3%
Fatigue
5%
19%
Edema
2%
2%
Skin toxicity
10%
3%
Other medical reason
17%
19%
Personal reasonB
26%
7%
A
Patients could be counted in more than one category, if they had more than one RDI
reduction for different reasons. i.e. a patient who had one cycle delayed for fatigue and
another cycle delayed for pain would be counted in both categories.
B
Personal reasons included vacations, patient preference or convenience, as well as
convenience delays between treatments that were not noted to be due to any medical reason.
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DISCUSSION
The primary aim of this study was to evaluate the association between
demographic, clinical, and lifestyle factors, such as BMI, diet, and physical activity, and
pCR from neoadjuvant chemotherapy for breast cancer. Secondarily, we investigated if
RDI was associated with pCR, and if the factors from the pCR analysis were associated
with suboptimal RDI. Additionally, we described the reasons recorded in the medical
record for suboptimal RDI.
The results of our primary analysis found that lower BMI prior to breast cancer
diagnosis is associated with pCR from neoadjuvant chemotherapy (p=0.04), and BMI
remained an independent predictor of pCR in the adjusted analysis. Although we
hypothesized that pCR would be related to RDI, we did not find an association between
pCR and completing chemotherapy with an optimal RDI of greater than 85%. We found
that nearly a quarter of patients (24%) had RDI below 85%, and 61% had RDI reduced
below 100%.
Pathologic Complete Response
We found that a lower BMI at the time of breast cancer diagnosis is associated
with higher rates of pCR in both the univariate and multivariate analyses. This finding
aligns with other studies showing that lower BMI is related to improved breast cancer
outcomes (30-32, 76). There is also a growing body of recent evidence to suggest that
lower BMI is associated specifically with pCR in patients receiving neoadjuvant
chemotherapy (36, 39, 40). For example, in a study of 1,169 patients receiving
neoadjuvant chemotherapy for invasive breast cancer, Litton and colleagues found that
patient with obesity and who are overweight were significantly less likely to have a pCR
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than patients of normal weight (36). The authors of that study suggest that possible
reasons for the relationship between BMI and lower pCR rates to chemotherapy could be
due to lower effectiveness of chemotherapy in patients with obesity.
However, our findings contradict the results of a few studies that did not find any
association between pre-diagnosis BMI and pCR from neoadjuvant chemotherapy (37,
38, 77). A pooled analysis of 1672 breast cancer patients enrolled in four different
neoadjuvant chemotherapy trials did not find a significant association between increasing
BMI and pCR rates (77). It should be noted that this study included patients who were all
enrolled in clinical trials, whereas our study which excluded patients treated on clinical
trial regimens. Kogawa and colleagues conducted a retrospective analysis of 1002 breast
cancer patients and did not find an association between BMI and pCR, or overall survival
(37). They did find, however, that increasing BMI over the course of neoadjuvant
chemotherapy treatment was associated with higher pCR rates in patients with initially
lower or normal BMIs. In contrast, Bao and colleagues did not find an association
between changes in BMI over the course of neoadjuvant chemotherapy treatment and
pCR rates in a cohort of 173 patients with triple-negative breast cancer (78). In our study,
we did not find an association between change in BMI and pCR, but we did not stratify
by initial BMI.
One mechanism that may explain the link between increased BMI and worse
breast cancer outcomes is through components of MetS such as triglycerides,
hypertension, and elevated blood glucose. In our study, we did not find that patients
taking medications for diabetes, hypertension, and hyperlipidemia had lower rates of
pCR. Although there is some evidence in the literature that higher levels of insulin
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resistance are associated with worse breast cancer outcomes, there is a paucity of
literature on whether features of metabolic syndrome other than BMI are associated with
pCR for neoadjuvant chemotherapy (67).
In a smaller subset of patients who were able to be reached for a telephone survey,
we evaluated whether physical activity prior to breast cancer diagnosis may lead to
improved outcomes from neoadjuvant chemotherapy. There is existing evidence that
higher levels of physical activity following breast cancer diagnosis may lead to improved
breast cancer survival (46-50). Although we had a small sample size for patients
answering the physical activity questionnaire, our exploratory analysis did not find an
association between physical activity prior to breast cancer diagnosis and pCR from
neoadjuvant chemotherapy. This finding agrees with several studies that did not find an
association between physical activity prior to breast cancer diagnosis and overall
outcomes from breast cancer, although these studies were not specific to neoadjuvant
chemotherapy (52, 56). For example, one study of 1,327 breast cancer patients by Borch
and colleagues did not find that pre-diagnosis physical activity levels were associated
with all-cause or breast cancer-specific mortality (52).
However, there have been a number of studies that did find associations between
higher pre-diagnosis physical activity and greater survival after breast cancer (48, 51, 5355). The relationship between pre-diagnosis physical activity and breast cancer outcomes
may be dependent on factors such as hormone-receptor status that we did not have a large
enough sample size to investigate. For example, the relationship between pre-diagnosis
physical activity and breast cancer outcomes may be dependent on factors such as
hormone-receptor status. Schmidt and colleagues found that recreational activity during
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the 3 years prior to diagnosis was associated with a 34% lower risk of death for women
with ER-positive tumors, but not ER-negative tumors (54).
It is well accepted that HR-negative tumors have higher rates of pCR than HR
positive tumors (5, 10), and our findings confirmed this (p<0.0001). Our finding that
AJCC stage at diagnosis was a predictor of pCR was also unsurprising given the known
improved outcomes from being diagnosed at an earlier stage (3).
Relative Dose Intensity
Adequate dose intensity of chemotherapy (RDI >85%) has been shown to be
important for treatment success and has been associated with longer disease-free survival
for women treated with adjuvant chemotherapy for breast cancer (26, 27, 79). We
hypothesized that receiving an optimal RDI of chemotherapy (>85%) would be
associated with pCR from neoadjuvant treatment. The existing literature on this topic
consists of a study of 141 Chinese breast cancer patients, which found that patients who
received more than 6 cycles of neoadjuvant chemotherapy had higher rates of pCR than
those who received less than 6 cycles (29). Our study did not find an association between
RDI >85% and pCR, showing our hypothesis to be incorrect. Although RDI has been
established as a valuable predictor of overall mortality, our results suggest that the benefit
of receiving the optimal dose intensity of chemotherapy may not be seen in the relatively
short timeframe in which pCR is measured after treatment. Rather, the positive effects of
receiving the optimal dose of neoadjuvant chemotherapy are more long-term than the
pathological outcome at the time of surgery.
We utilized the same factors from the pCR analysis to determine if these
demographic, clinical, or lifestyle factors were associated with RDI. Our univariate
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analysis of the associations with adequate RDI (>85%) found that patients who were
younger and premenopausal were more likely to have RDI >85%. Age and menopausal
status are strongly related, so it is not possible to tell the independent effects of these
factors. We also found a trend suggesting that patients taking medications for diabetes,
hypertension, or hyperlipidemia were less likely to have an RDI >85% (p=0.056). There
is some existing literature that suggests a relationship between diseases associated with
metabolic syndrome and reduced RDI, as a study by Bhatnagar and colleagues found that
patients with diabetes had a higher risk of neuropathy-related dose reductions when
treated with taxane-based chemotherapy regimens (80). We did not find an association
between BMI and adequate RDI.
Prior literature that found a survival benefit from increased physical activity
during breast cancer treatment have suggested the effect may be due to patients being
able to tolerate a greater dose intensity of treatment (48). Although the subset of patients
completing the telephone survey was small, the results of our exploratory analysis
suggest that patients who exercise at or above CDC-recommended levels prior to breast
cancer diagnosis were more likely to maintain RDI above 85%. However, the results of
this exploratory analysis should be interpreted cautiously as we did not have adequate
power to detect a difference in RDI by physical activity level.
It merits further discussion that our study did not find BMI to be associated with
RDI, but our exploratory analysis found that lower activity level may be associated with
lower RDI. This suggests that a patients’ activity level may be more related to a patient’s
ability to tolerate chemotherapy than their BMI. Additionally, our finding that BMI is
associated with pCR, but not with RDI merits additional investigation in future studies.

38
This suggests that they may be a biologic component, such as lower efficacy of the
chemotherapeutic agents in patients with higher BMI, that accounts for the relationship
between higher BMI and low pCR, rather than patients with higher BMI being less able
to tolerate chemotherapy.
Our finding in the exploratory analysis that weekly alcohol intake more than one
drink per week is associated with RDI > 85% is unexpected. It has been shown that
higher alcohol intake is associated with an increased risk of breast cancer and worse
treatment outcomes (69, 81). It is possible that this finding is due to a cofounder that we
did not measure and that drinking more than one alcoholic drink per week is a surrogate
for another factor that leads to better ability to tolerate chemotherapy. Interestingly,
existing literature suggests that habitual alcohol consumption may be related to lower
incidences of chemotherapy-induced nausea and vomiting in breast cancer patients (82).
It should be noted as well that the alcohol data came from the survey cohort with a
smaller sample size.
A key finding of our study is the high number of patients who had RDI <85%,
which is considered to be a clinically-significant factor associated with worse outcomes
(23). Sixty-one percent of the cohort had reduced RDI below 100%, and almost a quarter
of patients received less than 85% of the prescribed dose intensity. This is in accordance
with data published by Denduluri and colleagues in 2015 (59). They looked at dose
delays, reductions, and RDI across a wide range of breast cancer chemotherapy regimens
in patients treated in community oncology practices. They found that the percent of
patients with RDI <85% was greatest for those receiving anthracycline/
cyclophosphamide to docetaxel (45%), and lowest for those receiving dose-dense
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anthracycline/ cyclophosphamide to paclitaxel every two weeks (16%). The authors of
this study state that reduced dose intensity was more common in patients with obesity and
those with limited daily activities, suggesting a possible association between activity and
chemotherapy completion, though this was not measured directly in their study. In
addition, a 2018 study by Zhang and colleagues found that about 30% of patients
received RDI <85%, which is approximately the same as our findings (23).
The most common reasons for reduced RDI (dose reductions or delays) in the
cohort of patients with RDI <85% were neuropathy and myelosuppression. This is not
surprising, given that most patients in the study were on a regimen containing a taxane
agent, and that the most common dose-limiting side effect of taxane agents is peripheral
neuropathy (83). It is also important to note that our results show a high number of dose
delays due to personal reasons. About a quarter of patients with RDI <85% had at least
one cycle delayed due to a personal reason, which includes both physician-initiated
convenience delays and patient requests or missed appointments. Given the known
therapeutic benefit of maintaining adequate RDI, further work should investigate ways to
minimize these non-medical treatment adjustments. Neuropathy and myelosuppression
were also the top reasons for chemotherapy adjustment noted by Van Waart and
colleagues in a trial of patients undergoing adjuvant chemotherapy for breast cancer (59).
The high numbers of patients who experienced side effects impacting receipt of their
breast cancer treatments highlights the importance of finding interventions that can help
patients tolerate the full therapeutic dose, potentially including physical activity and
managing comorbid conditions.
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Limitations
Our study has several limitations. This study was conducted at a single academic
medical center, and a high percentage of the patients were white, which may limit the
generalizability of the findings. Our ability to measure metabolic syndrome markers was
limited by the absence of lab results (A1C, triglycerides, LDL) in the EMR for most
patients. We therefore utilized prescriptions for medications used to treat diabetes,
hypertension, and hyperlipidemia as an imperfect surrogate for these metabolic syndrome
markers.
We only measured chemotherapy side effects in patients who had a dose delay or
reduction, which limited our ability to determine which chemotherapy side effects are
predictive of pCR or having RDI <85%. We therefore were unable to determine if
patients without RDI reductions did not have side effects, or if their side effects were not
severe enough to warrant chemotherapy adjustments.
Another limitation of this study is the limited sample size, especially given the
relatively small number of participants we were able to reach for the telephone survey.
This limited the power of our analysis related to physical activity, diet, and alcohol
intake. We also did not have adequate power to perform subgroup analyses on how these
factors relate to other clinical or demographic information such as tumor stage, hormonereceptor status, and BMI. The physical activity data was self-reported and required recall
about past activities, and therefore may not be as reliable as more objective means of
measuring activity such as with activity trackers. Similarly, our questionnaire for
assessing diet quality (fruit and vegetable intake) and alcohol consumption required recall
of the past and may not be as accurate as methods such as daily food logs or weekly
alcohol intake questionnaires.
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Conclusions
We sought to investigate the association between lifestyle factors including BMI,
physical activity, and diet and pCR from neoadjuvant chemotherapy for breast cancer. To
our knowledge, this is the first study to investigate the relationship between RDI and pCR
in neoadjuvant chemotherapy patients. We found that a higher BMI is associated with
lower rates of pCR. We did not find an association between pCR and the RDI of
neoadjuvant chemotherapy. However, RDI still remains a valuable predictor of overall
mortality, and 24% of our cohort of breast cancer patients at a large academic medical
center received less than the optimal RDI of treatment (85%). Neuropathy was the most
common reason for reductions in RDI.
Further research with a larger sample size, more objective measures of physical
activity, and data on markers of metabolic syndrome is needed to investigate the
relationship between physical activity, metabolic syndrome, and outcomes from
neoadjuvant chemotherapy. The results of this study highlight the importance of lifestyle
behaviors, especially those mitigating high BMI, to improve the likelihood of breast
cancer treatment success in terms of pathologic outcomes. Our results also demonstrate
the substantial proportion of patients who do not receive adequate dose intensity of
chemotherapy, and future studies should investigate methods for increasing the
tolerability of chemotherapy and minimizing interruptions to treatment.
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